AIROS Medical’s Post

By getting more cardiomyopathy patients tested, we can potentially save and improve lives and help advance cardiomyopathy research and therapies. Learn more at: https://lnkd.in/gTyRtptn #cardiomyopathy #dilatedcardiomyopathy #geneticcardiomypathy #geneticscardiomyopathyawareness

Despite treatment advances, multiple myeloma remains incurable, with many patients relapsing or becoming resistant to treatment. Earn up to 2.0 credits/contact hours in this 3-episode Med Table Talk® series on RRMM and BCMA-Directed Therapies. Experts from the US and Western Europe have candid conversations about the role of BCMA in MM, clinical implications of new and emerging BCMA-directed therapies, and practical strategies for treatment sequencing. https://mli.link/bcma #CME #ECMEC #EBAH

Second Line Treatment of FL: Chart-based Market Dynamics - More than 75% of 2L patients are initiated treatment with chemoimmunotherapy - One-third of 2L patients are considered ASCT eligible but of these eligible patients, only about one-third actually receive the transplant. Meaning, approximately 10% of patients in 2L are treated with ASCT. Dive deeper into the results from our SAPPHIRE tracker on FL in Germany > https://hubs.ly/Q0283FZY0 #SAPPHIRE #Follicularlymphoma #CAR-T #Healthcaremarketresearch #Bispecifics

CDC estimates that 12.1 million people in the United States will have atrial fibrillation (AF) by 2030. Meanwhile, in Europe, it is estimated that 14 to 17 million people will suffer from atrial fibrillation by 2030, with 120,000 to 215,000 new cases each year. While this condition is generally not life-threatening, untreated atrial fibrillation can increase the likelihood of certain serious illnesses, such as heart failure, diabetes, dementia, hypertension, and even stroke. The concerns on soaring prevalence of atrial fibrillation drove the collaboration between Roche Diagnostics and FibriCheck. Through the open innovation program called Startup Creasphere, Roche Diagnostics and FibriCheck collaboration team was exploring how the digital solutions provided by the FibriCheck application can be strengthened for screening undiagnosed atrial fibrillation patients. Find out more by visiting our article: https://lnkd.in/gwu982bD #fibricheck #rochediagnostics #openinnovation #innovation #workshop #consulting #incubation #innovatewithinnovesia

We are thrilled to highlight Xiaoling Janice Ye, PhD and her groundbreaking research on kidney transplant failure and dialysis after graft loss (DAGL), showcased at this year's ERA conference. Xiaoling's study delves into the specific needs of DAGL patients, comparing their mortality and morbidity risks with transplant-naïve dialysis starters, using data from over 360,000 patients across 41 countries.    🔬 Key Findings:    ⏺︎ DAGL patients have an equivalent survival probability to transplant-naïve starters.  ⏺︎ Younger patients with higher inflammation levels are significant in the DAGL group.  ⏺︎ The study underscores the importance of specialized management for DAGL patients.  ⏺︎ Join us in celebrating Xiaoling's contributions to renal research and the potential for improved patient outcomes. Watch her brief video to learn more about her study's impact. https://lnkd.in/evsdsn3h #RenalResearch #ERACongress #KidneyTransplant #Dialysis #MedicalResearch 

A groundbreaking study, by Sarah Sinclair, explores the uncharted territory of utilising cannabinoids in the treatment of critically ill patients. 🌟 This study, the first of its kind, involved surveying over 650 physicians working in intensive care units across Germany. It aimed to shed light on the administration of cannabinoids to critically ill patients and its frequency in recent years. The results showed that while there were some reservations, several physicians had indeed used cannabinoids, with dronabinol being the most common choice. The primary reasons included metabolic and psychological distress, medication conservation, and addressing pain and nausea. 🌡 The findings emphasize the need for further research in this emerging field, as more doctors acknowledge the potential benefits of cannabinoids in critical care. The journey to unlock their full potential has just begun! #maxineravafoundation #cannabisresearch #curecancer #hopeinresearch #nonprofitorganisation #cannabiscures #fightcancer #makingadifference #cannabisaustralia #canceraustralia

New Insights in Alzheimer's Treatment: APOE Genotype and Therapy Risks 🧠 Recent studies highlight that Alzheimer’s patients carrying the APOE ε4 allele show a significantly increased risk for adverse effects from new anti-amyloid (beta) therapies. APOE genotyping is crucial for assessing the patient`s individual risk prior to applying these drugs. With Alzheimer’s cases on the rise, more personalized approaches in treatment are becoming more and more essential in managing the disease effectively. #AlzheimersDisease #APOE #Genotyping #Healthcare #EUROIMMUN

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma https://buff.ly/48E3iA6 #AETOSWire #Health #Treatment #Europe

A recent study on hepatic cytoreduction for rare lung and renal #NETs unveils insights from 21 patients: 🔺57% women, average age 60 years. 🔺90% of patients had extra-hepatic metastases. 🔺Surgical outcomes varied; 52% patients had full metastasis removal. 🔺Complications observed in 19% of cases, no mortalities. 🔺5-year liver-PFS: 65%; median time to progression: 66 months. 🔺Median survival time: 71 months. 🔺10-year survival rates approaching 39%. Tailored post-op therapies show promise for improved outcomes. https://ow.ly/HWxz50QEYe0 #MedEd

𝐓𝐡𝐞 𝐟𝐞𝐰 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 🌟 𝐕𝐢𝐞𝐰 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://bit.ly/3TEifgF 📈Increase in Obese and #ageingpopulation across the #globe 📈Genetical Cause of Primary #lymphedema 📈Awareness of #compression Products by Consumers 📈About 7 Million Lymphedema patients are present in the #unitedstates 📈Approximately 5% of the #adultpopulation affected by Chronic Venous Insufficiency 📈Early stage of Chronic Venous Disease, #compressiontherapy is the standard of care 📈Increase and prevalence of #cancers and #treatment of cancers leads to lymphedema conditions 3Mcompany, Bio Compression Systems, Convatec, DJO, medi GmbH & Co. KG, Medtronic, SIGVARIS GROUP, Smith+Nephew, Tactile Medical, Medi Supplies Canada Inc., Essity, Cardinal Health #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand